Compare · ICCC vs NEOG
ICCC vs NEOG
Side-by-side comparison of ImmuCell Corporation (ICCC) and Neogen Corporation (NEOG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ICCC and NEOG operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NEOG is the larger of the two at $1.97B, about 22.5x ICCC ($87.8M).
- Over the past year, ICCC is up 46.6% and NEOG is up 64.7% - NEOG leads by 18.1 points.
- NEOG has hit the wire 3 times in the past 4 weeks while ICCC has been quiet.
- NEOG has more recent analyst coverage (5 ratings vs 0 for ICCC).
- Company
- ImmuCell Corporation
- Neogen Corporation
- Price
- $9.86-0.70%
- $9.07+1.85%
- Market cap
- $87.8M
- $1.97B
- 1M return
- +9.92%
- -1.94%
- 1Y return
- +46.62%
- +64.70%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1987
- 1989
- News (4w)
- 0
- 3
- Recent ratings
- 0
- 5
ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Neogen Corporation
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.
Latest ICCC
- ImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by ImmuCell Corporation
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026
- Amendment: SEC Form 10-K/A filed by ImmuCell Corporation
- ImmuCell Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement
- ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026
- SEC Form DEF 14A filed by ImmuCell Corporation
- SEC Form 3 filed by new insider Dimarco Anthony
- SEC Form 3 filed by new insider Guillemette Gilles
- SEC Form 4 filed by Turner Kathy V
Latest NEOG
- Chief Accounting Officer Moylan John Patrick covered exercise/tax liability with 2,553 units of Restricted Stock Units, decreasing direct ownership by 10% to 23,571 units (SEC Form 4)
- SEC Form SD filed by Neogen Corporation
- Former Chief Legal Officer Rocklin Amy M exercised 35,183 shares at a strike of $9.29 and covered exercise/tax liability with 10,241 shares, increasing direct ownership by 44% to 82,182 units (SEC Form 4)
- Chief Accounting Officer Moylan John Patrick exercised 4,558 shares at a strike of $9.53 and covered exercise/tax liability with 1,568 shares, increasing direct ownership by 21% to 17,337 units (SEC Form 4)
- Chief Legal Officer Stacey Jennifer Evans was granted 39,349 shares (SEC Form 4)
- Neogen's Listeria Right Now™ Test Receives AOAC® Performance Tested Methods℠ Certification
- Neogen Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 3 filed by new insider Stacey Jennifer Evans
- SEC Form 10-Q filed by Neogen Corporation
- Neogen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits